Metronidazole is still the drug of choice for treatment of anaerobic infections

Clinical Infectious Diseases

Volumn 50, Issue SUPP.1, 2010, Pages

  Löfmark, Sonja ^a   Edlund, Charlotta ^a   Nord, Carl Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; AMEBIASIS; ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ANTIBIOTIC RESISTANCE; BACTEROIDES; BACTEROIDES FRAGILIS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG INDICATION; DRUG SAFETY; GASTRODUODENAL ULCER; GASTROINTESTINAL INFECTION; GIARDIASIS; HELICOBACTER PYLORI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOZOAL INFECTION; ROSACEA; SEIZURE; TRICHOMONIASIS; VAGINITIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIPROTOZOAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; DRUG THERAPY, COMBINATION; HUMANS; METRONIDAZOLE; PROTOZOAN INFECTIONS;

EID: 75749110963     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/647939     Document Type: Conference Paper

References (57)

1. Shinn DLS. Metronidazole in acute ulcerative gingivitis. Lancet 1962;279:1191.
2. Tally FP, Sutter VL, Finegold SM. Metronidazole versus anaerobes: in vitro data and initial clinical observations. Calif Med 1972;117:22-26
3. Tally FP, Sutter VL, Finegold SM. Treatment of anaerobic infections with metronidazole. Antimicrob Agents Chemother 1975;7:672-675
4. Freeman CD, Klutman NE, Lamp KC. Metronidazole: a therapeutic review and update. Drugs 1997;54:679-708.
5. Miller MA. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007;45(Suppl 2):S122-8.
6. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-307
7. Gerding DN, Muto CA, Owens RC, Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl l):S32-42.
8. Matthaiou DK, Peppas G, Bliziotis IA, Falagas ME. Ciprofloxacin/ metronidazole versus beta-lactam-based treatment of intra-abdominal infections: a meta-analysis of comparative trials. Int J Antimicrob Agents 2006;28:159-165 (Pubitemid 44223980)
9. WangS,CunhaBA,HamidNS,AmatoBM,FeuermanM,MaloneB. Metronidazolesingleversusmultipledailydosinginseriousintraabdominal/ pelvicanddiabeticfootinfections.JChemother2007;19:410-416(Pubitemid47236520)
10. Land KM, Johnson PJ. Molecular basis of metronidazole resistance in pathogenic bacteria and protozoa. Drug Resist Updat 1999;2:289-294
11. Diniz CG, Santos SG, Pestana AC, Farias LM, Carvalho MA, Auxiliadora M. Chromosomal breakage in the B. fragilis group induced by metronidazole treatment. Anaerobe 2000;6:149-153
12. Reysset G. Genetics of 5-nitroimidazole resistance in Bacteroides species. Anaerobe 1996;2:59-69.
13. Moore JM, Salama NR. Mutational analysis of metronidazole resistance in Helicobacter pylori. Antimicrob Agents Chemother 2005;49:1236-1237
14. Theron MM, Janse Van Rensburg MN, Chalkley LJ. Nitroimidazole resistance genes (nimB) in anaerobic Gram-positive cocci (previously Peptostreptococcus spp.). J Antimicrob Chemother 2004;54:240-242
15. Lofmark S, Fang H, Hedberg M, Edlund C. Inducible metronidazole resistance and nim genes in clinical Bacteroides fragilis group isolates. Antimicrob Agents Chemother 2005;49:1253-1256
16. Breuil J, Dublanchet A, Truffaut N, Sebald M. Transferable 5-nitroimidazole resistance in the Bacteroides fragilis group. Plasmid 1989;21: 151-154
17. Leiros HK, Kozielski-Stuhrmann S, Kapp U, Terradot L, Leonard GA, McSweeney SM. Structural basis of 5-nitroimidazole antibiotic resistance: the crystal structure of NimA from Deinococcus radiodurans. J Biol Chem 2004;279:55840-55849
18. Whittle G, Shoemaker NB, Salyers AA. The role of Bacteroides conjugative transposons in the dissemination of antibiotic resistance genes. Cell Mol Life Sci 2002;59:2044-2054
19. The European Committee on Antimicrobial Susceptibility Testing. Available at: http://www.eucast.org. 10 October 2009.
20. Pumbwe L, Chang A, Smith RL, Wexler HM. BmeRABC5 is a multidrug efflux system that can confer metronidazole resistance in Bacteroides fragilis. Microb Drug Resist 2007;13:96-101.
21. Pumbwe L, Glass D, Wexler HM. Efflux pump overexpression in multiple-antibiotic-resistant mutants of Bacteroides fragilis. Antimicrob Agents Chemother 2006;50:3150-3153
22. Sander P, Papavinasasundaram KG, Dick T, et al. Mycobacterium bovis BCG recA deletion mutant shows increased susceptibility to DNAdamaging agents but wild-type survival in a mouse infection model. Infect Immun 2001;69:3562-3568
23. Gal M, Brazier JS. Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole-resistant mutants. J Antimicrob Chemother 2004;54:109-116
24. Diniz CG, Arantes RM, Cara DC, et al. Enhanced pathogenicity of susceptible strains of the Bacteroides fragilis group subjected to low doses of metronidazole. Microbes Infect 2003;5:19-26.
25. Lai CH, Kuo CH, Chen PY, Poon SK, Chang CS, Wang WC. Association of antibiotic resistance and higher internalization activity in resistant Helicobacter pylori isolates. J Antimicrob Chemother 2006;57:466-471
26. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001;1: 101-114 (Pubitemid 33586045)
27. Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-iniected patients. J Antimicrob Chemother 1999;44:629-640 (Pubitemid 29532841)
28. BerganT,SolhaugJH,SoreideO,LeineboO. Comparativepharmacokineticsofmetronidazoleandtinidazole andtheirtissuepenetration.ScandJGastroenterol1985;20:945-950(Pubitemid16236018)
29. Shoemaker NB, Vlamakis H, Hayes K, Salyers AA. Evidence for extensive resistance gene transfer among Bacteroides spp. and among Bacteroides and other genera in the human colon. Appl Environ Microbiol 2001;67:561-568
30. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol 2004;12:412-416 (Pubitemid 39178592)
31. Scott KP. The role of conjugative transposons in spreading antibiotic resistance between bacteria that inhabit the gastrointestinal tract. Cell Mol Life Sci 2002;59:2071-2082
32. Hedberg M, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003;9:475-488
33. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007;51:1649-1655
34. Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001;45:1238-1243 (Pubitemid 32231006)
35. Tally FP, Cuchural GJ, Jacobus NV, et al. Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother 1983;23:536-540
36. Fille M, Mango M, Lechner M, Schaumann R. Bacteroides fragilis group: trends in resistance. Curr Microbiol 2006;52:153-157
37. Vieira JMBD, Boente RF, Rodrigues Miranda K, Avelar KES, Domingues RMCP, Candida de S Ferreira M. Decreased susceptibility to nitroimidazoles among Bacteroides species in Brazil. Curr Microbiol 2006;52:27-32.
38. Wybo I, Pierard D, Verschraegen I, et al. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2007;59:132-139 (Pubitemid 46017916)
39. Behra-Miellet J, Calvet L, Mory F, et al. Antibiotic resistance among anaerobic Gram-negative bacilli: lessons from a French multicentric survey. Anaerobe 2003;9:105-111 (Pubitemid 36970207)
40. Horn R, Robson HG. Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents. J Antimicrob Chemother 2001;48:127-130
41. Kommedal O, Nystad TW, Bolstad B, Digranes A. Antibiotic susceptibility of blood culture isolates of anaerobic bacteria at a Norwegian university hospital. APMIS 2007;115:956-961 (Pubitemid 47256281)
42. KochCL,DerbyP,AbrattVR.In- vitroantibioticsusceptibilityandmolecularanalysisofanaerobicbac teriaisolatedinCapeTown,SouthAfrica.JAntimicrobChemother1998;42: 245-248(Pubitemid28393595)
43. Roberts SA, Shore KP, Paviour SD, Holland D, Morris AJ. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003. J Antimicrob Chemother 2006;57:992-998
44. Ulger TN, Celik C, Cakici O, Soyletir G. Antimicrobial susceptibilities of Bacteroides fragilis and Bacteroides thetaiotaomicron strains isolated from clinical specimens and human intestinal microbiota. Anaerobe 2004;10:255-259
45. Papaparaskevas J, Pantazatou A, Katsandri A, Legakis NJ, Avlamis A. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece. Clin Microbiol Infect 2005;11:820-824 (Pubitemid 41341715)
46. Brazier JS, Stubbs SL, Duerden BI. Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned? J Antimicrob Chemother 1999;44:580-581
47. Hecht DW. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe 2006;12:115-121 (Pubitemid 43831678)
48. Jousimies-Somer HR, Summanen P, Citron DM, Baron EJ, Wexler HM, Finegold SM. Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Belmont, CA: Star Publishing, 2002.
49. Boyanova L, Kolarov R, Mitov I. Antimicrobial resistance and the management of anaerobic infections. Expert Rev Anti Infect Ther 2007;5:685-701. (Pubitemid 47250139)
50. Ingham HR, Eaton S, Venables CW, Adams PC. Bacteroides fragilis resistant to metronidazole after long-term therapy. Lancet 1978;1:214.
51. Rotimi VO, Khoursheed M, Brazier JS, Jamal WY, Khodakhast FB. Bacteroides species highly resistant to metronidazole: an emerging clinical problem? Clin Microbiol Infect 1999;5:166-169
52. Wareham DW, Wilks M, Ahmed D, Brazier JS, Millar M, Anaerobic sepsis due to multidrug-resistant Bacteroides fragilis: microbiological cure and clinical response with linezolid therapy. Clin Infect Dis 2005;40:e67-8.
53. Nguyen MH, Yu VL, Morris AJ, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000;30:870-876
54. Wong SS, Woo PC, Luk WK, Yuen KY. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999;34:1-6.
55. Johnson S, Sanchez JL, Gerding DN. Metronidazole resistance in Clostridium difficile. Clin Infect Dis 2000;31:625-626
56. Freeman J, Stott J, Baines SD, Fawley WN, Wilcox MH. Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 2005;56:988-989
57. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17: 1333-1343